Main Subject - Finance

Overview

Aid channels are proliferating and new large, non-traditional donors are appearing on the scene, contributing to aid fragmentation. Another complication is earmarking, which occur

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

s when funds are targeted by bilaterals, philanthropic funds, and other contributors for discrete purposes like malaria, AIDS, education or disaster relief. This complicates efforts to harm

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

onize and align aid, including through the 2005 Paris Declaration on Aid Effectiveness.

According to the 2007 GMR, total ODA from the 22 members of the OECD-Development Assistance Committe

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

, or DAC, fell in 2006 to $103.9 billion, after having climbed to $106.8 billion in 2005. This may point to a widening gap between aid commitments and delivery, which is worrying, given tha

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

t the international community is only three years away from the target to double aid to Africa by 2010 and donors have yet to make good on the promise that debt cancellation must be additio

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

al to aid increases.

Welcome signs of change are appearing, however. Two-thirds of donors now place strategic priority on implementing the 2005 Paris Declaration. A 2006 baseline survey fo

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

r monitoring the Paris Declaration surfaces some of the constraints facing donors and partner countries and identifies areas of promise. At the country level, comprehensive national strateg

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

es are being developed and links to operational frameworks are being improved, but there is significant room for improvement. Regarding donor actions, around two-thirds of aid is disbursed

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

on time and over 40 percent of aid is provided through program-based approaches such as budget support and sector-wide approaches; yet only a quarter of donor missions are undertaken jointl

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

and only 54 percent of country analytic work is jointly prepared.

Aid Promises, Commitments, and Disbursements

Participants in Monterrey in 2002 recognized that a substantial increase in

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

foreign aid and other resources would be required if developing countries were to achieve the MDGs. Developed countries were urged to “make concrete efforts” to increase ODA to the UN targ

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

et of 0.7 percent of GNP1. The Africa Action Plan announced at the 2002 G8 Leaders Summit in Kananaskis, Canada suggested that half or more of new development assistance could be directed t

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

Africa. At the UN World Summit in 2005, countries reaffirmed the so-called Monterrey Consensus, recognizing the importance of enhancing the aid effort, particularly in Africa. At the 2005

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

G8 Summit in Gleneagles, Scotland, G8 and other donors made a “Renewed Commitment to Africa” which included a pledge to increase the amount of ODA allocated to Africa by $25 billion a year

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

y 2010, more than doubling aid to Africa compared to 2004. Since then, donors’ progress toward fulfilling their commitments has been modest. Helping Africa to develop will be a key focus of

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

the June 2007 G-8 Leaders’ Summit in Heilgendamm, Germany.

The amount of financing actually flowing to developing countries – that is disbursements – is vitally important. Net ODA disburs

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ments from DAC countries were about $3 billion in 2006, following a record $27 billion increase in 2005 (in nominal terms). The decline reflects debt relief returning to more normal levels,

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

following two extraordinary Paris Club agreements in 2005-- Iraq received a record $13.9 billion in debt relief from its Paris Club creditors in 2005 and Nigeria received nearly $11 billio

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

. At Monterrey, donors pledged that debt relief would not displace other components of ODA. Excluding debt relief, ODA fell by 1.8 percent in 2006, compared with a 9.7 percent increase in 2

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

005. Relative to Gross National Income in DAC donor countries, ODA dipped to 0.3 percent in 2006, after reaching 0.33 percent in 2005, and remains well short of the UN target of 0.7 percent

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.mainsubjects.org.ua/article/89443/mainsubjects-World-Bank-Funding.html">World Bank Funding</a>

BB link (for phorums):
[url=http://www.mainsubjects.org.ua/article/89443/mainsubjects-World-Bank-Funding.html]World Bank Funding[/url]

Much has been going on about SEO for websites, but with the evolution of blogs, it is important to recognize that some tweaks are needed to for most blog templates, to optimize for search engines.

Electronic commerce or ecommerce is used to describe doing business over the Internet. Selling products and services to customers over the Internet can be accomplished a number of ways and various levels of sophistication.

Chances are you have a list of customers that have purchased once or twice from you in the past but with whom you’ve lost contact. You're always going to have people that buy once and never purchase again but once they stop buying, that's lost revenue for your business. To stay in business these days you must persuade your one-time purchasers into buying again and again.

Tags

Links

Main Subject - World Bank Funding

Related Articles: